<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="389">
  <stage>Registered</stage>
  <submitdate>10/09/2003</submitdate>
  <approvaldate>10/09/2003</approvaldate>
  <nctid>NCT00068601</nctid>
  <trial_identification>
    <studytitle>S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer</studytitle>
    <scientifictitle>Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>S0230</secondaryid>
    <secondaryid>CDR0000327758</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <healthcondition>Infertility</healthcondition>
    <healthcondition>Menopausal Symptoms</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - cyclophosphamide
Treatment: drugs - goserelin acetate

Active Comparator: Standard Chemotherapy - Patients receive cyclophosphamide-containing chemotherapy alone.

Experimental: Chemotherapy Plus Goserelin - Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy. Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity.


Treatment: drugs: cyclophosphamide
Part of planned chemotherapy regimen

Treatment: drugs: goserelin acetate
Given subcutaneously

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Rate of Premature Ovarian Failure at 2 Years - Ovarian failure at two years is defined as amenorrhea (absence of menstrual bleeding) for the preceding six months AND the presence of follicle-stimulating hormone (FSH) in the post-menopausal range.</outcome>
      <timepoint>2 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of Ovarian Dysfunction at 2 Years - Ovarian dysfunction is defined as amenorrhea for the preceding three months and the presence of FSH, estradiol and/or inhibin B levels in the postmenopausal range.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of Ovarian Dysfunction at 1 Year - Ovarian dysfunction is defined as amenorrhea for the preceding three months and the presence of FSH, estradiol and/or inhibin B levels in the postmenopausal range.</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically confirmed invasive breast cancer

               -  Stage I-IIIA

               -  Operable disease

          -  Bilateral synchronous invasive breast cancer allowed provided primary tumors were
             diagnosed no more than 1 month apart and both tumors are hormone receptor negative

          -  Must be planning to receive 3-8 months of a preoperative or postoperative chemotherapy
             regimen containing alkylating agents (anthracyclines or non-anthracyclines), meeting 1
             of the following criteria:

               -  3-month/4-course anthracycline-based regimen

               -  6- to 8-month/course anthracycline-based regimen

               -  6- to 8-month/course non-anthracycline-based regimen

          -  Hormone receptor status:

               -  Estrogen receptor negative

               -  Progesterone receptor negative

        PATIENT CHARACTERISTICS:

        Age

          -  18 to 49

        Sex

          -  Female

        Menopausal status

          -  Premenopausal

        Performance status

          -  Zubrod 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective barrier contraception

          -  No other prior malignancy except adequately treated basal cell or squamous cell skin
             cancer or any in situ cancer from which the patient has been disease-free for at least
             5 years after treatment with curative intent

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  See Disease Characteristics

          -  No prior cytotoxic chemotherapy

        Endocrine therapy

          -  No other concurrent hormonal therapy

        Radiotherapy

          -  Concurrent radiotherapy to the breast, chest wall, or lymph nodes allowed

        Surgery

          -  See Disease Characteristics

        Other

          -  Concurrent participation in other therapeutic clinical trials, including SWOG-S0221,
             allowed</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>49</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Supportive Care</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>257</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,TAS,VIC,WA</recruitmentstate>
    <hospital>Mater Hospital - North Sydney - North Sydney</hospital>
    <hospital>Royal North Shore Hospital - St. Leonards</hospital>
    <hospital>Newcastle Mater Misericordiae Hospital - Waratah</hospital>
    <hospital>Royal Adelaide Hospital Cancer Centre - Adelaide</hospital>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>Ballarat Oncology and Haematology Services - Ballarat</hospital>
    <hospital>Box Hill Hospital - Box Hill</hospital>
    <hospital>Monash Medical Center - Clayton Campus - Clayton</hospital>
    <hospital>Peter MacCallum Cancer Centre - East Melbourne</hospital>
    <hospital>Maroondah Hospital - East Ringwood</hospital>
    <hospital>St. Vincent's Hospital - Melbourne - Fitzroy</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>2060 - North Sydney</postcode>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>2298 - Waratah</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>7000 - Hobart</postcode>
    <postcode>3350 - Ballarat</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3002 - East Melbourne</postcode>
    <postcode>3135 - East Ringwood</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>6000 - Perth</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Huy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Oostende</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Verviers</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bergamo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Biella</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Carpi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lecco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bellinzona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Lausanne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Locarno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Lugano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Mendrisio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Thun</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Southwest Oncology Group</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Cancer and Leukemia Group B</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Eastern Cooperative Oncology Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>International Breast Cancer Study Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Goserelin blocks hormone production in the ovaries. It is not yet known whether
      ovarian suppression using goserelin will prevent ovarian failure (early menopause) in women
      receiving chemotherapy for breast cancer.

      PURPOSE: This randomized phase III trial is studying how well giving goserelin together with
      chemotherapy works compared with chemotherapy alone in preventing early menopause in women
      with stage I, stage II, or stage IIIA breast cancer.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00068601</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Halle C Moore, MD</name>
      <address>The Cleveland Clinic</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>